Cargando…
Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4
Maturity onset diabetes of the young (MODY) is a rare form of diabetes mellitus typically seen in young adults that results from pancreatic beta-cell dysfunction. MODY4 is a rare subtype caused by a PDX1 mutation. In this case, we present a nonobese 26-year-old male with polyuria and polydipsia. Lab...
Autores principales: | Mangrum, Christian, Rush, Eric, Shivaswamy, Vijay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624095/ https://www.ncbi.nlm.nih.gov/pubmed/26543388 http://dx.doi.org/10.4137/CMED.S31926 |
Ejemplares similares
-
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022) -
Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014) -
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014) -
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
por: Richter, Bernd, et al.
Publicado: (2008) -
Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011)